JP Morgan Maintains Overweight on Seaport Therapeutics, Raises Price Target to $41
Benzinga Newsdesk 3 hours ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Tessa Romero maintains Seaport Therapeutics (NASDAQ:SPTX) with a Overweight and raises the price target from $40 to $41.
JP Morgan analyst Tessa Romero maintains Seaport Therapeutics (NASDAQ:SPTX) with a Overweight and raises the price target from $40 to $41.